IPG Photonics (IPGP) investor relations material

Deal rationale and strategic fit

• Expands presence in high-margin medical laser markets, notably ophthalmology, complementing existing strengths in urology and dermatology, and accelerates strategic evolution into higher-growth segments.

• Increases addressable medical market by approximately $1 billion, bringing total above $2 billion.

• Combines complementary technologies, commercial capabilities, and applications expertise to drive innovation and future growth.

• Builds a scaled medical laser platform with broader commercial reach and clinical credibility.

• Strengthens business mix by increasing advanced solutions revenue from 16% to 26% of total pro forma sales.

Financial terms and conditions

• Purchase price is €300 million, representing 15.9x 2025 adjusted EBITDA, paid in cash at closing on a cash-free, debt-free basis.

• Includes a contingent earn-out of up to €50 million based on 2026 and 2027 financial performance, tied to revenue and EBITDA targets.

• Acquisition funded entirely through cash on hand, maintaining strong post-transaction balance sheet and financial flexibility.

• Expected to be accretive to gross margin, EBITDA, and adjusted EPS in the first year.

Synergies and expected cost savings

• No near-term cost synergies anticipated due to carve-out structure, but long-term value expected from new product co-development and leveraging technical and operational leadership.

• Potential for future integration of proprietary laser technologies, subject to regulatory timelines.

• Combines established leadership in ophthalmology and urology to create a scaled medical laser platform.